CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 232 enrolled
Drug / intervention
[123I]ß CIT and SPECT imagingdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00117819
NCT00117819Phase 2Completed

Dynamic SPECT Imaging With [123I] B-CIT in Individuals With Parkinsonian Syndrome (PS) and in Individuals at Risk for Parkinsonian Syndrome

Institute for Neurodegenerative Disorders·interventional·Posted Jul 8, 2005·Updated May 2, 2014

In Brief

A Phase 2 clinical trial evaluating [123I]ß CIT and SPECT imaging for Parkinsonian Syndrome. Completed, enrolled 232 participants across 1 site.

Detailed Summary

This study involves study participants who have been clinically diagnosed with parkinsonian syndrome or who are at-risk for parkinsonian syndrome, have a family history of parkinsonian syndrome or exposure to environmental toxins potentially associated with parkinsonian syndrome. Participants will have brain imaging to assess dopamine transporter density. The imaging data coupled with family history and environmental exposure data may provide important information about potential risk factors for parkinsonian syndrome.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States

Timeline

Phase 2CompletedFinished
200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJul 8, 2005
Enrollment StartMar 1, 2001
Primary CompletionJan 1, 2013
TodayJul 2, 2026
Enrollment to primary: 11.8 yearsPosted 21.0 years ago

Interventions

[123I]ß CIT and SPECT imagingdrug

To assess \[123I\]ß CIT and SPECT imaging